Health
Cardiovascular drug trial setbacks hit Novartis and Novo Nordisk therapies
Novartis and Novo Nordisk experienced consecutive cardiovascular drug clinical failures, according to STAT.
The short version
- Novartis and Novo Nordisk suffered consecutive cardiovascular drug trial setbacks.[STAT]
- Novartis announced that its drug pelacarsen failed a seven-year clinical trial targeting lipoprotein a.[STAT]
- An estimated 20% of individuals have elevated levels of lipoprotein a, which increases risks of severe heart conditions.[STAT]
- The failure complicates ongoing efforts by competitors investing billions of dollars in similar lipid-lowering treatments.[STAT]
Key facts
- Novartis and Novo Nordisk faced consecutive failures in cardiovascular drug trials.[STAT]
- Novartis disclosed that its candidate pelacarsen did not succeed in a seven-year clinical trial.[STAT]
- Pelacarsen was engineered to decrease strokes or heart attacks by reducing lipoprotein a levels.[STAT]
- Roughly 20% of the population has abnormally high amounts of lipoprotein a.[STAT]
- Multiple pharmaceutical firms have invested billions of dollars developing competing treatments for the same lipid target.[STAT]
What remains uncertain
- The long-term feasibility and clinical viability of other companies' pipeline medications targeting lipoprotein a remain unclear following the trial failure.[STAT]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.